CES 2022: Seoul Semiconductor to Exhibit All Light Sources Including MICRO DISPLAY Required for Autonomous Driving of Future Vehicle
22.12.2021 07:44:00 EET | Business Wire | Press release
At CES 2022, Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a global optical semiconductor company, will demonstrate a Micro Display for vehicle (WICOP mc) to communicate with pedestrians or oncoming drivers during autonomous driving, and a solution to sterilize the in-vehicle air. In addition, the company will demonstrate WICOP ADB (Adaptive Driving Beam: Intelligent Headlamp), which improves the visibility of oncoming vehicles or pedestrians while driving. WICOP, the basic technology of these two solutions (WICOP mc and WICOP ADB), has already been applied to about 10% of vehicles worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211221005796/en/
Differences between the 1st and 2nd generation of WICOP technology, products named COB or CSP produced by technology theft (Graphic: Business Wire)
So far, the focus has been on developing technologies for preventing automobile accidents and ensuring driver safety. However, technology that prioritizes the convenience and safety of not only drivers but also passengers, pedestrians, bicycle riders, or other vehicle drivers is becoming very important. In particular, along with automobile indoor sterilization technology to make the air inside a vehicle safe, the lighting communication technology, which can reassure drivers of other vehicles or pedestrians when the driver of an autonomous vehicle is either absent or distracted, is receiving great attention.
With the development of autonomous driving systems, the technology that allows vehicles to recognize surrounding objects is also in the process of development. By the way, the current brightness of LCD or OLED displays less than 1,000 nits has limitations in implementing lighting communication with pedestrians or other vehicles. In addition, the existing LED display chips are large in size, so they cannot properly implement a necessary message on a small bumper or on the exterior of a vehicle. Seoul Semiconductor's dust-proof and moisture-proof WICOP mc realizes a 5000-nits display that is eight times brighter than the existing LCD and can display clear messages.
Seoul Semiconductor is conducting virus sterilization experiments using an actual car in the in-house laboratory to study the safety of passengers from various bacteria and viruses. At CES 2022, Seoul Semiconductor will demonstrate to its VIP customers a solution that can sterilize more than 90% of the viruses floating inside the car within 10 minutes. Seoul Semiconductor will begin mass production of its sterilization technology, Violeds, in January at one of the top five global companies.
"Seoul Semiconductor is the only company in the world that is able to produce and supply a total solution for all light sources from EPI to PKG, from UV LEDs required for automobiles, to Blue, Green, Red, IR LEDs, and even VCSEL laser diodes," a Seoul Semiconductor official said. “At CES 2022, innovation to all solutions will be separately disclosed to VIP customers who have been specially reserved.”
About Seoul Semiconductor
Seoul Semiconductor is the world’s second-largest global LED manufacturer, a ranking excluding the captive market, and has more than 10,000 patents. Based on a differentiated product portfolio, Seoul offers a wide range of technologies, and mass produces innovative LED products for indoor and outdoor lighting, automotive, IT products, such as mobile phones, computer displays, and other applications, as well as the UV area. The company’s world’s first development and mass production products are becoming the LED industry standard and leading the global market with a package-free LED, WICOP; a high-voltage AC-driven LED, Acrich; an LED with 10X the output of a conventional LED, nPola; a cutting edge ultraviolet clean technology LED, Violeds; an all direction light emitting technology, filament LED; a natural sun spectrum LED, SunLike; and more. For more information, please visit www.seoulsemicon.com/en.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211221005796/en/
Contact information
Seoul Semiconductor Co., Ltd.
Jinseop Jeong
+82-70-4391-8555
jjs8732@seoulsemicon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom